The Phantom Achilles: Paul George’s Silent Collapse in Philadelphia

The Philadelphia 76ers’ 2024-25 season began with high hopes, especially after acquiring Paul George on a four-year, $212 million contract. However, what was anticipated as a championship-caliber roster quickly unraveled due to a series of injuries that sidelined key players, including George.

In his debut game for the Sixers, George showcased his potential, scoring 15 points despite a loss to the Phoenix Suns. Yet, this performance was a fleeting glimpse of what could have been. Shortly after, he suffered a hyperextended knee, a recurrence of an injury from the preseason, leading to a bone bruise that kept him out for several games. This setback marked the beginning of a season plagued by physical challenges.

As the season progressed, George’s injuries compounded. He experienced groin soreness, ankle issues, and a torn tendon in his left pinkie finger, all of which affected his performance. Despite these challenges, he continued to play, often using pain management strategies to remain on the court. However, his effectiveness diminished, and his frustration became evident.

By March, the situation had deteriorated further. George received injections in his left adductor muscle and knee, but the persistent injuries led to his early exit from the season. With only 41 games played, his season ended prematurely, leaving the 76ers to grapple with the implications of his absence.

This series of events raises questions about the team’s medical management and the long-term viability of relying on aging players with injury histories. The Sixers’ gamble on George has yet to pay off, and the future remains uncertain.